XML 31 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Note 3 - Related Party Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Feb. 29, 2020
Aug. 21, 2017
Feb. 29, 2020
Dec. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Nov. 26, 2019
Dec. 31, 2018
Apr. 16, 2018
Mar. 31, 2017
Equity Method Investment, Other than Temporary Impairment         $ (13,000)        
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total         (4,743,000) (2,047,000)        
Assets, Current, Total       $ 9,861,000 13,395,000          
Liabilities, Current, Total       6,685,000 6,481,000          
Amortization of Accelerated Debt Discount Due to Conversion         2,486,000        
Amortization of Debt Discount (Premium)         522,000 586,000        
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]                    
Debt Conversion, Original Debt, Amount     $ 3,000,000              
Debt Conversion, Converted Instrument, Shares Issued (in shares)     1,666,670              
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]                    
Debt Instrument, Convertible, Conversion Price (in dollars per share)               $ 1.80 $ 16.10  
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]                    
Line of Credit Facility, Maximum Borrowing Capacity         10,000,000         $ 10,000,000
Proceeds from Long-term Lines of Credit     $ 1,869,000              
Long-term Line of Credit, Total         7,582,000          
Amortization of Accelerated Debt Discount Due to Conversion         $ 2,486,000          
Debt Instrument, Interest Rate, Stated Percentage         22.00%          
Debt Instrument, Convertible, Beneficial Conversion Feature $ 1,869,000                  
Debt Instrument, Unamortized Discount, Total         $ 1,869,000          
Amortization of Debt Discount (Premium)         546,000 586,000        
Interest Payable         443,000 461,000        
Boyalife W.S.N. [Member]                    
Distributor Agreement Term (Year)   3 years                
Distributor Agreement, Renewal Term (Year)   2 years                
Accounts Receivable, Related Parties         $ 0 $ 266,000        
ImmuneCyte [Member]                    
Proceeds from Issuance of Common Stock       $ 3,000,000            
ImmuneCyte [Member] | Common Class A [Member]                    
Stock Issued During Period, Shares, New Issues (in shares)       600,000            
Shares Issued, Price Per Share (in dollars per share)       $ 5            
ImmuneCyte [Member]                    
Equity Method Investment, Ownership Percentage       18.87% 18.87%   20.00%      
Joint Venture Purchase, Percent of Company's Cost             115.00%      
Line of Credit Facility, Maximum Borrowing Capacity             $ 1,000,000      
Equity Method Investment, Aggregate Cost         $ 0   $ 28,000      
Equity Method Investment, Other than Temporary Impairment         (13,000)          
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total         (264,000)          
Assets, Current, Total         2,561,000          
Liabilities, Current, Total         $ 50,000          
ImmuneCyte [Member] | HealthBanks Biotech [Member]                    
Equity Method Investment, Ownership Percentage       75.47%     80.00%      
ImmuneCyte [Member] | Private Institution [Member]                    
Equity Method Investment, Ownership Percentage       5.66%